Brief: Portage Biotech resumes enrollment in final group of its early-stage study for its cancer treatments
Brief: Portage Biotech Re-Launches Adenosine Unit As Independently Managed Co
U.S. STOCKS ON THE MOVE-Cloudflare, Ecolab, Honda Motor
U.S. STOCKS ON THE MOVE-Children's Place, Nordson, Kosmos Energy
U.S. STOCKS ON THE MOVE-Tesla, Cloudflare, Zimmer Biomet
Portage Biotech soars on potential deal with Immunova
Brief: Portage Biotech Announces Letter Of Intent With Immunova For An Option To Acquire Iox Therapeutics
Brief: Portage Biotech Says CFO Allan Shaw Departed From Co
Brief: Portage Biotech Regains Compliance With Nasdaq Listing Rule 5550(A)(2)
Brief: Portage Biotech Announces 1-For-20 Reverse Stock Split
Brief: Portage Biotech Plans To Expand Its Evaluation Of Strategic Alternatives
Brief: Immuno-Oncology Company Portage Biotech Completes Monetization of Intensity Therapeutics Shares
Portage Biotech Inc reports results for the quarter ended in December - Earnings Summary
Portage Biotech Inc expected to post a loss of 27 cents a share - Earnings Preview
Brief: Portage Biotech Reports Business And Strategic Update
Brief: Portage Biotech Collaborates With Merck To Study 2 Next-Gen Adenosine Antagonists In Combination With Keytruda In Solid Tumors
Portage Biotech Inc reports results for the quarter ended in June - Earnings Summary
Portage Biotech Inc expected to post a loss of 24 cents a share - Earnings Preview
Portage Biotech Inc expected to post a loss of 27 cents a share - Earnings Preview